Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of$ 0.04. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this pharmaceutical company would post a loss of$ 0.08 per share when it actually produced a loss of $0.02, delivering a surprise of 75%. Over the last four quarters, the compa ...